Italy, Capua (CE), February 8th, 2021 – Pierrel S.p.A, a full service global provider for life science, biopharma and pharmaceutical industries listed on the Italian Stock Exchange has announced the marketing of the Orabloc Needlestick Safety System in the U.S.,
The system is a single-use needle protection device that covers the end of needles after use to minimize the risk of needle sticks. The device is designed to also meet CDC and
OSHA requirements for one-handed needle containment.
The device is preloaded with 100 color-coded capsules that can be used with all needle lengths and gauges. It can also be used with bent or angled needles. The Orabloc Needlestick device adopts an easy-to-use, spring-loaded system that automatically advances to the next capsule after one capsule is removed. The color coding provides a visual notification when the device is running low on capsules. The Orabloc safety device helps protect against accidental needle sticks during recapping and temporary storage or when disposing of the needle in a sharp’s container. It also has a non-skid silicone bottom
to ensure stability on any surface while allowing for portability.
The Orabloc Needlestick Safety System, joins the injectable dental anesthetic, Orabloc, marketed in the U.S. since 2011, and redefines needle stick safety protocol. Branding the device as a private label of a patented product, Orabloc, the Needlestick Safety System
builds upon the product franchise.
“This innovative device is a product extremely in line with the current market needs for greater secutity and is a safe and practical alternative to current methods available for supporting compliance of the OSHA Bloodborne Pathogen standards” said Fabio Velotti,
CEO of Pierrel Pharma.
For more information, visit orabloc.com/orabloc-needlestick-safety-system
Pierrel S.p.A. listed on the Italian Stock Exchange since May 2006, is today a full service global provider for life science, biopharma and pharmaceutical industries. Pierrel Group, through its two business Divisions, is specializedinpharmaceutical manufacturing (Contract Manufacturing Division), and in the development, registration and licensing of new drugs and medical devices (Pharma Division). The company has over 60 years experience in the pharmaceutical industry and is one of the leading European manufacturers of local and dental anesthetics. The manufacturing site has a modern aseptic production line, approved by AIFA and FDA, and regularly inspected by these two agencies. The subsidiary Pierrel Pharma S.r.l. has registered and distributes dental anaesthetic Orabloc® in Canada, USA, Russia and Europe. Pierrel S.p.A head quarter is located in Italy in Capua (CE) near Naples. www.pierrelgroup.com
For more information:
Pierrel S.p.A.
Investor Relator
Dott. Fulvio Citaredo
E-mail: investor.relations@pierrelgroup.com
phone. +39 0823 626 111
fax +39 0823 626 228
Spriano Communication & Partners S.r.l. Media Relations Cristina Tronconi
E-mail: ctronconi@sprianocommunication.com
phone. + 39 3460477901
Jacopo Ghirardi
E-mail: ufficiostampa@sprianocommunication.com
phone. +39 3337139257
Products 26 August 2026
Lumos 3DX Mobile Dental Imaging System Brings Advanced Diagnostics Chairside
New solution from Valkyrie BioScience delivers chairside Tomosynthesis and Intelligent Imaging to bridge the gap between 2D and CBCT.
News 26 August 2026
Premier to broaden clinician access to Forward Science’s FDA-cleared, non-drug oral wound dressing for post-procedural periodontal care
News 26 August 2026
Recognition reflects more than three decades of sustained growth for the integrated healthcare support organization
Editorials 26 August 2026
Achievement and service take center stage as the University of Colorado Anschutz School of Dental Medicine honors the Doctor of Dental Surgery (DDS) Class of 2026.
Oral Hygiene & Prevention 26 August 2026
Propolis-containing formulations in caries prevention - a systematic review and meta-analysis.
This peer-reviewed oral hygiene & prevention article summarizes clinical evidence from Clinical oral investigations (2026). It focuses on findings that may help dental professionals evaluate...